Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

Lorcan McGarvey, Surinder S. Birring, Alyn H. Morice, Peter V. Dicpinigaitis, Ian Pavord, Jonathan Schelfhout, Allison Martin Nguyen, Qing Li, Anjela Tzontcheva, Beata Iskold, Stuart A. Green, Carmen La Rosa, David Muccino, John A. Smith